Vancouver, British Columbia–(Newsfile Corp. – October 21, 2020) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that two poster presentations regarding iCo’s Oral Amphotericin B technology (iCo-019) will be highlighted at the AAPS 2020 PharmSci 360 Virtual Meeting October 26 – November 5, 2020.
AAPS is the preeminent global scientific organization of more than 10,000 actively participating pharmaceutical scientists from industry, academia, government, and other related research institutes. The mission of AAPS is to advance the capacity of pharmaceutical scientists to develop medicines that improve health.
Dr. Kishor M. Wasan, Director of Research at iCo Therapeutics Inc., Distinguished University Scholar Adjunct Professor in the Faculty of Medicine at the University of British Columbia (UBC) and Co-Director of the Neglected Global Diseases Initiative at UBC (NGDI-UBC), stated, “We are very excited to
present our research at this internationally renowned conference and discuss the progress of our technology with the pharmaceutical sciences community.” Dr. Wasan, along with co-authors Drs. Peter Hnik, Director and Chief Medical Officer of iCo, and Ellen Wasan Assistant Professor at the University of Saskatchewan, will present the following two poster presentations:
Phase Ia and Ib Double-Blind Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (ICO-019) in Healthy Human Subjects. https://www.eventscribe.com/2020/PharmSci360/fsPopup.asp?Mode=posterinfo&PosterID=290734
Assessing the Pharmacokinetics and Biodistribution of Amphotericin B following Oral Administration of Three Novel Oral Amphotericin B Formulations to Beagle Dogs. https://www.eventscribe.com/2020/PharmSci360/fsPopup.asp?Mode=posterinfo&PosterID=290710
“As previously reported despite the current COVID-19 pandemic there continues to be a great deal of interest in iCo-019 for the treatment of fungal and parasitic infections. We continue to have a number positive discussions with potential partners to help further the clinical development of iCo-019,” noted Dr. Wasan.
“Although the Covid-19 pandemic is affecting clinical trials world-wide, iCo is actively preparing for a Phase 2 clinical study in vulvovaginal candidiasis) or, alternatively, in visceral leishmaniasis,” stated Dr. Peter Hnik.
About iCo Therapeutics
iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus areas and if so, the Company will generally seek to capture further value via partnerships. iCo shares trade on the TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”.
For more information, visit the Company website at: www.icotherapeutics.com. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Certain statements included in this press release may be considered “forward-looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by words such as: “anticipate”, “intend”, “plan”, “goal”, “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include statements relating to the timing and completion of the Private Placement and the use of proceeds therefrom. All forward-looking statements are based on iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations iCo Therapeutics Inc. 1-604-800-9860